Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 16/20 | 0.63 |
| ▸ | KISS1R | Q969F8 | 1/20 | 0.47 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.46 |
| ▸ | TMPRSS11D | O60235 | 1/20 | 0.44 |
| ▸ | CTRL | P40313 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11932326 | 0.95 | OPRK1 (0.70) | OPRK1KISS1ROPRM1 | |
| SCHEMBL21286606 | 0.94 | OPRK1 (0.65) | OPRK1KISS1RPSMB5OPRM1TMPRSS11D | |
| SCHEMBL21233374 | 0.93 | OPRK1 (0.56) | OPRK1KISS1R | |
| SCHEMBL21286484 | 0.92 | OPRK1 (0.62) | OPRK1OPRM1 | |
| SCHEMBL10316438 | 0.92 | OPRK1 (0.74) | OPRK1OPRM1 | |
| SCHEMBL19249834 | 0.92 | OPRK1 (0.74) | OPRK1OPRM1 | |
| SCHEMBL24001326 | 0.92 | OPRK1 (0.68) | OPRK1KISS1RPSMB5OPRM1 | |
| SCHEMBL24360719 | 0.91 | OPRK1 (0.59) | OPRK1 | |
| SCHEMBL19249446 | 0.90 | OPRK1 (0.58) | OPRK1 | |
| SCHEMBL21286625 | 0.90 | OPRK1 (0.54) | OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210346505-A1 | Oral Formulations of Kappa Opioid Receptor Agonists | CARA THERAPEUTICS, INC. | 2021-11-11 | — | — | US | disclosed |
| US-11083726-B2 | Methods and compositions for treating vasomotor symptoms | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2021-08-10 | — | — | US | disclosed |
| US-20210030745-A9 | Methods and Compositions for Treating Vasomotor Symptoms | ACER THERAPEUTICS INC. | 2021-02-04 | — | — | US | disclosed |
| US-20190255037-A1 | Methods and Compositions for Treating Vasomotor Symptoms | UNIV WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2019-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210346505-A1 | Oral Formulations of Kappa Opioid Receptor Agonists | OPRK1, OPRL1, OGFR | OPRK1 1/4885KISS1R 694/4885PSMB5 2240/4885 |
| US-20210030745-A9 | Methods and Compositions for Treating Vasomotor Symptoms | VASP, PDE3A, PDE2A | OPRK1 554/4885KISS1R 1051/4885PSMB5 4100/4885 |
| US-20190255037-A1 | Methods and Compositions for Treating Vasomotor Symptoms | VASP, PDE3A, PDE2A | OPRK1 554/4885KISS1R 1051/4885PSMB5 4100/4885 |
| US-11083726-B2 | Methods and compositions for treating vasomotor symptoms | VASP, PDE3A, PDE2A | OPRK1 554/4885KISS1R 1051/4885PSMB5 4100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.